) -- Adam Feuerstein's take on the biotech week that was Nov. 1, 2010:

The week's best-performing stocks in the sector:

Avanir Pharmaceuticals



Aastrom Biosciences



Jazz Pharmaceuticals

(JAZZ) - Get Report


Repros Therapeutics


(+23%), and


(CRIS) - Get Report


It was

Hep C-apalooza in Boston

this week at the American Association for the Study of Liver Disease (AASLD) annual meeting, which included important updates from

Vertex Pharmaceuticals

(VRTX) - Get Report



(MRK) - Get Report

and others.

One guy who didn't enjoy his time at AASLD was Dr. Yves Benhamou,

arrested on criminal fraud charges

for allegedly tipping off a hedge fund with insider information about negative clinical trial results.

Bad Medicine: When Doctors Tip Off Wall Street


Cell Therapeutics

(CTIC) - Get Report

submitted the lymphoma drug pixantrone for European approval.

The top FDA drug approval pickers




received no bidders for the company.

Fear the Beard! The San Francisco Giants win the World Series!

FDA approves

Cadence Pharmaceuticals'


injectable painkiller Ofirmev but

investors sell the stock


FDA review of

Bristol-Myers Squibb's

(BMY) - Get Report

melanoma drug Ipilimumab extended three months. The new approval decision date is March 25, 2010.

Questcor Pharmaceuticals


launches Acthar as a treatment for infantile spasms.

The week's worst-performing stocks:




Angiotech Pharmaceuticals

( ANPI) (-44%),

AspenBio Pharma



ARYx Therapeutics


(-20%), and

Anthera Pharmaceuticals



Adventrx Pharmaceuticals


submits FDA approval application for the chemotherapy drug exelbine (ANX-530).

Biogen Idec

(BIIB) - Get Report

fires 15% of its workforce as part of a corporate restructuring and cost-cutting plan.

FDA Drug Approvals for October




Provenge sales, guidance fall short


Exact Sciences

(EXAS) - Get Report

prices 10 million shares at $6 a share.


(MNKD) - Get Report

Accused of Data Fraud Coverup


This week's

Biotech Stock Mailbag


Orexigen Therapeutics


, Exact Sciences,

Spectrum Pharmaceuticals

(SPPI) - Get Report

, Avanir Pharmaceuticals and MannKind.



Pharmaceuticals to launch gout drug Krystexxa on Nov. 30.



secret rebates to doctors who prescribe eye drug

(via New York Times)

CT scans help detect early lung cancer in smokers

(via New York Times)

Biovail (now

Valeant Pharmaceuticals


to hedge fund:

I'm sorry!

(via Pharmalot)


melanoma drug show promise

(via Reuters)

Conflict of interest rules: Going too far?

Judging by the low quality of recent FDA advisory panels, the answer is definitely "yes!" (via Pharmalot)

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here:

Adam Feuerstein


>To follow the writer on Twitter, go to


>To submit a news tip, send an email to:


Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.